ArticleCureus2024
Evaluation of the Clinicopathological Features Associated With Malignancy of Phyllodes Tumor of the Breast.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Multidisciplinary Perspective on Breast Phyllodes Tumors: A Literature Review.Medicina (Kaunas, Lithuania) · 2025Review
- Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePhyllodes tumor (PT) is a variant of fibroepithelial proliferations of the breast, histologically demonstrating a leaf-like pattern. The WHO has categorized PTs as benign, borderline, or malignant based on their histological characteristics. The objective of this paper is to assess the clinicopathological factors with malignancy in PT of the breast.
methodMedical records of 101 diagnosed PT patients in the Second Affiliated Hospital of Dalian Medical University between 2008 and 2023 were reviewed. Information on clinical presentation and histopathological findings of the lesions were retrieved from patient files and/or histological reports, respectively.
resultsOf the 101 patients, all were female and had a mean age of 44.35 ± 14.14 years and mean tumor size of 8.3 ± 5.8 cm The distribution for the histological type was benign (n = 54, 53.4%), borderline (n = 36, 35.6%) and malignant (n = 11, 10.8%). Most benign PTs were observed in younger patients, while borderline and malignant PTs involved elderly patients, with a mean age of 47.56 ± 11.86 years for borderline PT and a mean age of 46.55 ± 11.62 years for malignant PT. Benign PTs had a mean size of 5.58 ± 2.29 cm, while those of borderline and malignant were larger, with a mean size of 10.58 ± 6.79 cm and 14.90 ± 6.44 cm, respectively. Malignant PTs had higher lactate dehydrogenase (LDH) levels of 232 ± 91.5 U/L compared to borderline PTs, 177.9 ± 19.9 U/L, and benign PTs, 177.6 ± 39.9U/L. The course of the disease of the malignant PT group was slightly longer (436.9 ± 391.3 weeks) than that of the benign (44.17 ± 71.54 weeks) and borderline (54.33 ± 94.33 weeks). In histopathology, necrosis was observed only in malignant PTs (81.8%), and severe stromal atypia was seen in 72.7% of malignant cases. The mitotic count was highest in malignant PTs at 13.18 ± 4.43 HPF as compared to benign 3.52 ± 2.97 HPF and borderline PTs at 7.28 ± 2.21 HPF.
conclusionBenign PTs were more common in this study than malignant or borderline PTs. There was a highly significant correlation between patient age, tumor size, LDH, and disease progression in all subtypes of PT. This analysis showed that malignant PTs were larger and observed in older patients with higher LDH and with a longer duration of the disease. Other factors, in addition to histological properties, are useful in determining PT behavior and management. More studies at an advanced level of evidence in the form of randomized trials are required when developing a risk classification for PT based on patient age, tumor size, and LDH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.